Magnetic resonance imaging in rheumatoid arthritis advances and research priorities
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Magnetic resonance imaging in rheumatoid arthritis advances and research priorities. / Østergaard, Mikkel; McQueen, FM; Bird, P; Ejbjerg, B; Lassere, MN; Peterfy, CG; O'Connor, PJ; Haavardsholm, E; Shnier, R; Genant, HK; Emery, P; Edmonds, JP; Conaghan, PG.
I: Journal of Rheumatology, Bind 32, Nr. 12, 2005, s. 2462-4.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Magnetic resonance imaging in rheumatoid arthritis advances and research priorities
AU - Østergaard, Mikkel
AU - McQueen, FM
AU - Bird, P
AU - Ejbjerg, B
AU - Lassere, MN
AU - Peterfy, CG
AU - O'Connor, PJ
AU - Haavardsholm, E
AU - Shnier, R
AU - Genant, HK
AU - Emery, P
AU - Edmonds, JP
AU - Conaghan, PG
PY - 2005
Y1 - 2005
N2 - Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.
AB - Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.
M3 - Journal article
VL - 32
SP - 2462
EP - 2464
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 12
ER -
ID: 34061782